Makers of drugs and medical devices say the tariffs on goods from Canada, Mexico and China could have an outsized impact on ...

Pharmaceutical manufacturers may need new models to maintain sustainable businesses and support patients who cannot afford ...

The root of the U.S.’s high prescription drug prices lies in its unique system, which allows pharmaceutical manufacturers to ...

President Trump has ended a Biden administration effort to lower the cost of prescription drugs for people on Medicare and Medicaid.

IRA has unintended consequences on investment landscape for small- and large-molecule drugs stifling the development of new ...

President Donald Trump didn't wait long in his second term to begin shaking things up in Washington, D.C. In less than two ...

President Biden's time in office has finally expired. But his signature legislative accomplishment—the Inflation Reduction ...

Biden-era policies rescinded by Donald Trump could signal a significant shake-up in Medicare and Medicaid drug price reforms.

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

A bipartisan group of lawmakers wants to hike Medicare fees for doctors by 6.62%, offsetting inflation and cuts made this ...

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for older adults and people with disabilities.